arrow
S

Sarah J. Welsh

royal devon university healthcare nhs foundation trust
H指数:35
被引数:6,666

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2 Relationships Between Plasma KIM-1 Levels, Peripheral Immune Profiles and Disease-Free Survival Outcomes in the TransRAMPART Study

2 血浆KIM-1水平、外周免疫谱与无病生存结局之间的关系:TransRAMPART研究

2026-09-020
OAAI
Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised 13C-MRI and mass spectrometry imaging

使用临床高极化¹³C-MRI和质谱成像技术,探查1例富马酸水合酶缺陷型肾癌患者的肿瘤内代谢区室化。

2026-01-130
OAAI
Introduction of adjuvant immunotherapy into the renal surgery pathway: Are eligible patients receiving treatment in time in the UK NHS setting?

将佐剂免疫疗法引入肾脏手术路径:在英国NHS体系中,符合条件的患者是否能及时接受治疗?

2026-01-010
PRE
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI

评估透明细胞肾细胞癌新辅助治疗的代谢效应:采用高极化[1-13 C]丙酮酸MRI

2025-12-010
OAAI
Investigating the mechanisms of neoadjuvant olaparib and cediranib in renal cancer: results of arms 1 to 3 of the WIndow of opportunity in REnal cancer (WIRE) clinical trial

探究新辅助奥拉帕利和西地尼布在肾癌中的作用机制:WIndow of opportunity in REnal cancer (WIRE) 临床试验第1至3组的试验结果

2025-10-010
OAAI
Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

肾细胞癌静脉肿瘤血栓中轴突生的血管生成和免疫预测因子对新辅助阿昔替尼治疗反应的预测

2025-04-280
OA
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
2022-06-2331
OA
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

MEDI0680联合Durvalumab与Nivolumab单药治疗晚期或转移性透明细胞肾细胞癌患者的随机II期研究

2022-05-048
OAAI
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol

WIRE研究使用贝叶斯自适应设计的II期,多臂,多中心,非随机的机会窗口临床试验平台,用于证明可手术肾细胞癌的新型治疗策略的机制-研究方案

2021-11-188
OAAI